Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Intrathecal therapy with monoclonal antibodies in severe progressive multiple sclerosis

Trial Profile

Intrathecal therapy with monoclonal antibodies in severe progressive multiple sclerosis

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 10 Oct 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rituximab (Primary)
  • Indications Multiple sclerosis
  • Focus Adverse reactions
  • Acronyms ITT-PMS; PMSIT
  • Most Recent Events

    • 10 Oct 2018 Results published in the Neurology
    • 18 Nov 2016 Status changed from recruiting to completed.
    • 21 Aug 2015 Planned End Date changed from 1 Nov 2014 to 1 Jun 2016, as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top